Companies › Tyra Biosciences
3 active drug programs in 7 registered trials: 4 Phase 1, 3 Phase 2; Oncology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dabogratinib (TYRA-300) FGFR3-selective tyrosine kinase inhibitor | FGFR3 | Phase 2 | Low-grade NMIBC; Achondroplasia; Low Grade Upper Tract Urothelial Carcinoma; Healthy … | Nov 2026 |
| TYRA-200 FGFR 1/2/3 tyrosine kinase inhibitor | FGFR1, FGFR2, FGFR3 | Phase 1 | Locally Advanced Cholangiocarcinoma | Mar 2027 |
| TYRA-430 FGFR inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 1 | Metastatic Hepatocellular Carcinoma | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06006702 | Dabogratinib (TYRA-300) | Phase 1 | Healthy | Other | May 2025 |
| NCT05544552 | Dabogratinib (TYRA-300) | Phase 1 | Locally Advanced Urothelial Carcinoma | Oncology | Nov 2026 |
| NCT06160752 | TYRA-200 | Phase 1 | Locally Advanced Cholangiocarcinoma | Oncology | Mar 2027 |
| NCT06915753 | TYRA-430 | Phase 1 | Metastatic Hepatocellular Carcinoma | Oncology | Jan 2028 |
| NCT06995677 | Dabogratinib (TYRA-300) | Phase 2 | Low-grade NMIBC | Oncology | Feb 2028 |
| NCT06842355 | Dabogratinib (TYRA-300) | Phase 2 | Achondroplasia | Other | Jan 2030 |
| NCT07265947 | Dabogratinib (TYRA-300) | Phase 2 | Low Grade Upper Tract Urothelial Carcinoma | Oncology | Oct 2030 |
Cash of $456m on 2026-09-30; operating cash outflow about $129m a year; runway about 42 months at that burn, to Apr 2030; 2 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 13 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Elevar Therapeutics TransThera Sciences (Nanjing) TScan Therapeutics Radiopharm Theranostics Relay Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.